PHARMA DEALS DURING SEPTEMBER 2014
(Part 3 out of 3)

by Medius Associates

This table lists all the major pharma collaborations, acquisitions and mergers agreed during September 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Sigma Aldrich /  Merck KGaA	Company acquisition	Laboratory supplies	17,000
Alios / J&J	Company acquisition	Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV	1,750
Lumara Health / Amag Lumara Health / Perrigo	Company acquisition (excluding Perrigo products)	Maternal health business including orphan drug to reduce risk of preterm birth Makena Three women's health products	1,025 82
Merrimack / Baxter	Licence to commercialise1	MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III	970
Infinity / AbbVie	Licence and collaboration	IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia	805
Curevac / Boehringer Ingelheim	Licence and collaboration	Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer	601
Civitas / Acorda	Company acquisition	CVT-301 - Levodopa dry powder inhaler.  Phase IIb for treatment of Parkinsons + pulmonary delivery technology	525
AstraZeneca / Lilly	Licence and collaboration	Oral BACE inhibitor in phase I for Alzheimer's disease	500
Ambit Biosciences / Daiichi Sankyo	Company acquisition	Kinase inhibitor pipeline, lead compound quizartinib for AML in phase III	410
Aesica Pharmaceutical / Consort	Company acquisition	Aesica is a UK contract development and manufacturing company	374
Aspen / Mylan	Product acquisition2	Arixtra anticoagulant plus authorised generic version	300
Sutro / Merck KGaA	Licence and collaboration	Sutro's antibody drug conjugate technology for oncology	298
Rhizen / TG Therapeutics	Licence and collaboration3(exercise of option)	TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies	244
Seattle Genetics / Genmab	Licence and collaboration	Additional deal to use Seattle's antibody drug conjugate technology	211
Altor / Shenzhen Beike	Licence and collaboration4	ALT-803 an interleukin-15-based agonist in Phase I/II for treatment of various cancers	209
MyoKardia/ Sanofi	Licence and collaboration5	Three programmes for treatment of genetic forms of cardiomyopathy	200
Shasun / Strides Arcolab	Company acquisition	Shasun is an Indian API and generic company	200
Innovus / Sothema Labs Innovus / Orimed	Licence to commercialise6 Licence to commercialise7	Natural oils to treat female sexual desire disorder (Zestra) and various penile disorders (EjectDelay, Sensum)	171 86
Isopure / Glanbia	Company acquisition	Glanbia, US company selling premium branded sports nutrition powders and drinks	153
NeuroVive / OnCore	Licence and collaboration	NVP018 an oral sangamide-based  2nd generation cyclophilin inhibitor for hepatitis B	150

All deals are worldwide unless otherwise noted

1: Global excluding US and Taiwan

2: US only

3: Excludes India 

4: China only 

5: Excluding commercialisation in US

6: Middle East and Africa

7: Canada

Fuente: PMLiVE

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:

(translator on page)

¿Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

¿Cómo GERENCIAR EFICAZMENTE a partir del

MANAGEMENT ESTRATÉGICO?

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

¿Cómo GERENCIAR PROCESOS DE CAMBIO

y no sufrir en el intento?

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?

Recetas para Escenarios Turbulentos

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510